Literature DB >> 17455205

Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.

Akira Andoh1, Shinji Sakata, Yuhsuke Koizumi, Keiichi Mitsuyama, Yoshihide Fujiyama, Yoshimi Benno.   

Abstract

BACKGROUND: Terminal restriction fragment length polymorphism (T-RFLP) analysis is a powerful tool to assess the diversity of complexed microbiota. This permits rapid comparison of microbiota from many samples. In this study, we performed T-RFLP analysis of the fecal microbiota from patients with ulcerative colitis (UC).
METHODS: Forty-four patients with UC (23 women and 21 men, median age 25 years) and 46 healthy individuals (25 women and 21 men, median age 34 years) were enrolled in this study. DNA was extracted from their stool samples, and the 16S rRNA genes were amplified by PCR. The PCR products were then digested with HhaI and/or MspI restriction enzymes, and the length of the T-RF was determined.
RESULTS: The fecal microbial communities were classified in 8 clusters. Almost all the healthy individuals (39 of 46) were included in cluster I, and most of the UC patients could be divided into the other 7 clusters, indicating that fecal bacterial communities are different between healthy individuals and active UC patients. Some T-RFs, derived from the unclassified bacteria, Ruminococcus, Eubacterium, Fusobacterium, gammaproteobacteria, unclassified Bacteroides, and unclassified Lactobacillus, were detected in the UC patients, but not in the healthy individuals. The T-RFLP patterns were also different between the active patients and inactive (remission) patients. The T-RF derived from the unclassified bacteria, Ruminococcus and Eubacterium, and the T-RFs derived from the unclassified bacteria, Eubacterium, and Fusobacterium were predominantly detected in the active patients not the inactive patients. In contrast, the T-RFs derived from Lactobacillus and unclassified Lactobacillus were more predominant in the inactive (remission) patients. In 4 patients with proctitis, the pattern of fecal microbial diversity was very similar.
CONCLUSIONS: T-RFLP analyses showed that the diversity of fecal microbiota in patients with UC was different from that in healthy individuals. Unclassified bacteria, as well as known bacteria, can contribute to alterations in the bacterial diversity of UC patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17455205     DOI: 10.1002/ibd.20151

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  44 in total

1.  Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis.

Authors:  Hideyuki Nemoto; Keiko Kataoka; Hideki Ishikawa; Kazue Ikata; Hideki Arimochi; Teruaki Iwasaki; Yoshinari Ohnishi; Tomomi Kuwahara; Koji Yasutomo
Journal:  Dig Dis Sci       Date:  2012-05-24       Impact factor: 3.199

2.  The bacterial pathogenesis and treatment of pouchitis.

Authors:  S D McLaughlin; S K Clark; P P Tekkis; R J Nicholls; P J Ciclitira
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

Review 3.  The role of mucosal immunity and host genetics in defining intestinal commensal bacteria.

Authors:  Jonathan Hansen; Ajay Gulati; R Balfour Sartor
Journal:  Curr Opin Gastroenterol       Date:  2010-11       Impact factor: 3.287

4.  Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis.

Authors:  Ashis K Samanta; Valeria A Torok; Nigel J Percy; Suzanne M Abimosleh; Gordon S Howarth
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

5.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease.

Authors:  Akira Andoh; Hiroyuki Kuzuoka; Tomoyuki Tsujikawa; Shiro Nakamura; Fumihito Hirai; Yasuo Suzuki; Toshiyuki Matsui; Yoshihide Fujiyama; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2012-05-11       Impact factor: 7.527

6.  Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis.

Authors:  Akira Andoh; Hirotsugu Imaeda; Tomoki Aomatsu; Osamu Inatomi; Shigeki Bamba; Masaya Sasaki; Yasuharu Saito; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2011-01-21       Impact factor: 7.527

7.  Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

Authors:  Yasushi Yoshimatsu; Akihiro Yamada; Ryuichi Furukawa; Koji Sono; Aisaku Osamura; Kentaro Nakamura; Hiroshi Aoki; Yukiko Tsuda; Nobuo Hosoe; Nobuo Takada; Yasuo Suzuki
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 8.  Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota.

Authors:  C T Peterson; V Sharma; L Elmén; S N Peterson
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

9.  Terminal restriction fragment polymorphism analyses of fecal microbiota in five siblings including two with ulcerative colitis.

Authors:  Akira Andoh; Shinobu Ida; Tomoyuki Tsujikawa; Yoshimi Benno; Yoshihide Fujiyama
Journal:  Clin J Gastroenterol       Date:  2009-09-19

10.  Intestinal Host-Microbe Interactions under Physiological and Pathological Conditions.

Authors:  Rodrigo Bibiloni; Eduardo J Schiffrin
Journal:  Int J Inflam       Date:  2010-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.